Antiemetic Therapy — CPB 0724 | AETNA Coverage Update

Aetna modified CPB 0724 covering antiemetic therapy, effective October 21, 2025. Here's what billing teams need to know before submitting claims.

Aetna, a CVS Health company, updated its antiemetic therapy coverage policy under CPB 0724 in the Aetna system, touching a wide range of drugs and clinical scenarios across oncology, radiation therapy, and surgical settings. This policy spans over 200 CPT codes in the chemotherapy administration (96401–96424) and radiation treatment delivery (77371–77425) families, plus 145 HCPCS codes covering specific drug administration. If your practice bills antiemetic therapy alongside chemotherapy or radiation for Aetna members, this update affects your charge capture and medical necessity documentation right now.

Quick-Reference Table

Aetna Antiemetic Therapy Coverage Criteria and Medical Necessity Requirements 2025

The core structure of this coverage policy is step therapy. Aetna's medical necessity criteria are built around emetic risk levels and documented failure of first-line agents. That's not new — but the updated CPB 0724 sharpens the conditions under which higher-cost antiemetics clear the bar.

For cancer chemotherapy, Aetna organizes coverage around two first-line IV agents: granisetron (Kytril) and ondansetron (Zofran). These are the gatekeepers. Most of the more expensive agents only become medically necessary after documented failure of or contraindication to one of these two at FDA-recommended doses.

Palonosetron (Aloxi) and fosaprepitant dimeglumine (Emend) are covered for either of two scenarios. First, prevention of acute nausea or vomiting with moderate or highly emetogenic chemotherapy — including high-dose cisplatin. Second, treatment of nausea or vomiting from low or minimally emetogenic chemotherapy when IV granisetron or ondansetron at FDA-recommended doses has failed or is contraindicated.

Granisetron (Kytril), extended-release granisetron (Sustol), and ondansetron (Zofran) via IV are covered for prevention of acute and delayed nausea with moderate or highly emetogenic chemotherapy — and for low or minimally emetogenic chemotherapy when the oral versions have failed or are contraindicated. The oral-to-IV step requirement here is explicit. Document the oral failure before billing the IV administration.

The combination of palonosetron plus fosaprepitant is covered specifically for high emetic risk patients who have failed previous therapy with a steroid plus a 5-HT3 antagonist. That's a two-step failure requirement. Your documentation needs to show the prior regimen and the inadequate response.

Rolapitant (Varubi) and aprepitant (Cinvanti) are covered in combination with dexamethasone and a 5-HT3 serotonin receptor antagonist — given before IV antineoplastic therapy — for prevention of delayed nausea and vomiting with moderate or high emetic risk chemotherapy. Akynzeo injection (fosnetupitant/palonosetron) is covered in combination with dexamethasone for highly emetogenic chemotherapy only, covering both acute and delayed nausea prevention.

For radiation therapy, the policy covers dolasetron mesylate (Anzemet) for radiation-induced nausea and vomiting from total body irradiation (TBI) — but only after IV granisetron or ondansetron at FDA-recommended doses has failed or is contraindicated. IV granisetron or IV ondansetron for TBI-related nausea are covered when the oral versions have failed or are contraindicated. This applies across the radiation treatment delivery code range of CPT 77371 through 77425.

For postoperative nausea and vomiting (PONV), IV amisulpride (Barhemsys) is covered for members 18 and older in two scenarios. A single 5 mg IV dose at anesthesia induction prevents PONV — used alone or with a non-dopaminergic antiemetic like ondansetron, dexamethasone, or betamethasone. A single 10 mg IV dose treats PONV in adults who either received non-dopaminergic prophylaxis or had no prophylaxis at all. IV palonosetron, dolasetron mesylate, or fosaprepitant for PONV are covered when IV granisetron or ondansetron at FDA-recommended doses has failed or is contraindicated.

Prior authorization requirements for specific agents — particularly the newer or combination therapies — should be confirmed at the time of treatment planning. If your practice manages Aetna prior auth for oncology-related antiemetics, verify current PA thresholds against the updated CPB 0724 criteria before October 21, 2025 is fully baked into Aetna's claims adjudication.

Coverage Indications at a Glance

Aetna Antiemetic Therapy Billing Guidelines and Action Items 2025

The real issue here is documentation. Aetna's antiemetic billing denials almost always trace back to missing step-therapy evidence — not wrong codes. The coverage policy is built on escalating thresholds, and your claims need to reflect each step clearly.

CPT, HCPCS, and ICD-10 Codes for Antiemetic Therapy Under CPB 0724

Covered CPT Codes (When Selection Criteria Are Met)

The policy references over 200 CPT codes. Below are the primary families included in CPB 0724.

Chemotherapy Administration

Radiation Treatment Delivery

Other CPT Codes

The policy data includes 145 HCPCS codes covering specific antiemetic drug administration. The full HCPCS code list is available in the policy source document at CPB 0724 on Aetna's system. The policy data provided does not include specific ICD-10-CM code descriptions — reference the full policy document for the complete diagnosis code set.